VV | MedChemExpress (MCE) Life Science Reagents

By Targets:	Antibiotic (2) Bacterial (2) Endogenous Metabolite (2) HSV (1) Influenza Virus (1) Isotope-Labeled Compounds (1) Orthopoxvirus (2) RSV (1) SARS-CoV (2)
By Research Areas:	Infection (5)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-145119AS

Mindeudesivir hydrobromide JT001; VV116; GS-621763-d₁ hydrobromide	SARS-CoV RSV Influenza Virus	Infection
Mindeudesivir (JT001; VV116; GS-621763-d₁) hydrobromide is a deuterated version of Remdesivir (HY-104077), a highly orally active nucleoside antiviral against SARS-CoV-2 and respiratory syncytial virus (RSV). Mindeudesivir hydrobromide retains the antiviral activity of Remdesivir against COVID-19, and is the first domestically produced deuterium targeting the COVID-19 .

HY-145119S

Mindeudesivir JT001 free base; VV116 free base; GS-621763-d₁	Isotope-Labeled Compounds	Others
GS-621763-d₁ is the deuterium labeled GS-621763 (HY-145119) . GS-621763, an orally bioavailable proagent of GS-441524, shows antiviral activity against SARS-CoV-2 pathogenesis in mice .

HY-B0125

Ofloxacin 5+ Cited Publications Hoe-280	Bacterial Antibiotic Endogenous Metabolite Orthopoxvirus	Infection
Ofloxacin (Hoe-280) is a fluoroquinolone whose primary mechanism of action is inhibition of bacterial DNA gyrase. Ofloxacin shows inhibitory activity against vaccinia virus (VV).

HY-B0502A

Enrofloxacin monohydrochloride 5+ Cited Publications BAY Vp 2674 monohydrochloride; PD160788 monohydrochloride	Bacterial Antibiotic Endogenous Metabolite Orthopoxvirus	Infection
Enrofloxacin monohydrochloride (BAY Vp 2674 monohydrochloride) is an effective antibiotic with an MIC₉₀ of 0.312 μg/mL for Mycoplasma bovis. Enrofloxacin monohydrochloride shows inhibitory activity against vaccinia virus (VV).

HY-149023

HSV-1/HSV-2-IN-2	HSV	Infection
HSV-1/HSV-2-IN-2 is a HSV-1, HSV-2 and VV inhibitor with EC₅₀ values of 6.8, 8.9 and 8.9 µM, respectively. HSV-1/HSV-2-IN-2 shows antiviral activity .

HY-107931

Propiolactone β-propiolactone; 2-Oxetanone; Betaprone	SARS-CoV	Infection
Propiolactone (β-propiolactone; 2-Oxetanone) is a viral chemical inactivator that causes the infectious inactivation of viruses. Propiolactone was co-incubated with SARS-CoV at a ratio of 1:1000 (v:v) and used as a bacteriostatic agent to formulate the BPL-inactivated influenza virus vaccine (Flu-BPL) .

Cat. No.	Product Name

HY-L127

Anti-Orthopoxvirus Compound Library	36 compounds
Orthopoxvirus is a genus of viruses in the family Poxviridae and subfamily Chordopoxvirinae. The orthopoxvirus genus consists of 12 viruses including variola virus, vaccinia virus (VV), cowpox viruses (CV), monkeypox virus, and camelpox virus. Smallpox has been eradicated worldwide in 1980, but some other orthopoxvirus, such as monkeypox virus, are still threats to human health. There are not many drugs available for orthopoxvirus treatment. The only product currently available for treatment of complications of Orthopoxvirus infection is vaccinia immunoglobulin (VIG). In 2021, brincidofovir was approved by FDA for the treatment of smallpox and tecovirimat was approved by EMA for the treatment of monkeypox in 2022. A few active compounds including interferon and interferon inducers, and a variety of nucleosides or nucleotides have been reported to have activity against orthopoxvirus. MCE carefully prepared a unique collection of 36 compounds reported with the anti- orthopoxvirus activity which can be used for drug screening and other research about orthopoxvirus.

Anti-Orthopoxvirus Compound Library

36 compounds

Orthopoxvirus is a genus of viruses in the family Poxviridae and subfamily Chordopoxvirinae. The orthopoxvirus genus consists of 12 viruses including variola virus, vaccinia virus (VV), cowpox viruses (CV), monkeypox virus, and camelpox virus. Smallpox has been eradicated worldwide in 1980, but some other orthopoxvirus, such as monkeypox virus, are still threats to human health.

There are not many drugs available for orthopoxvirus treatment. The only product currently available for treatment of complications of Orthopoxvirus infection is vaccinia immunoglobulin (VIG). In 2021, brincidofovir was approved by FDA for the treatment of smallpox and tecovirimat was approved by EMA for the treatment of monkeypox in 2022. A few active compounds including interferon and interferon inducers, and a variety of nucleosides or nucleotides have been reported to have activity against orthopoxvirus.

MCE carefully prepared a unique collection of 36 compounds reported with the anti- orthopoxvirus activity which can be used for drug screening and other research about orthopoxvirus.

Cat. No.	Product Name	Target	Research Area

HY-P5364

B8R 20-27	Peptides	Others
B8R 20-27 is a biological active peptide. (This is amino acids 20 to 27 fragment of B8R, a vaccinia virus (VV) gene that encodes a secreted protein related to gamma interferon receptor. B8R binding to IFN-g neutralizes its antiviral activity.)

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B0125

Ofloxacin 5+ Cited Publications Hoe-280	Infection Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields	Bacterial Antibiotic Endogenous Metabolite Orthopoxvirus
Ofloxacin (Hoe-280) is a fluoroquinolone whose primary mechanism of action is inhibition of bacterial DNA gyrase. Ofloxacin shows inhibitory activity against vaccinia virus (VV).

HY-B0502A

Enrofloxacin monohydrochloride 5+ Cited Publications BAY Vp 2674 monohydrochloride; PD160788 monohydrochloride	Infection Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	Bacterial Antibiotic Endogenous Metabolite Orthopoxvirus
Enrofloxacin monohydrochloride (BAY Vp 2674 monohydrochloride) is an effective antibiotic with an MIC₉₀ of 0.312 μg/mL for Mycoplasma bovis. Enrofloxacin monohydrochloride shows inhibitory activity against vaccinia virus (VV).

Cat. No.	Product Name	Chemical Structure

HY-145119AS

Mindeudesivir hydrobromide
Mindeudesivir (JT001; VV116; GS-621763-d₁) hydrobromide is a deuterated version of Remdesivir (HY-104077), a highly orally active nucleoside antiviral against SARS-CoV-2 and respiratory syncytial virus (RSV). Mindeudesivir hydrobromide retains the antiviral activity of Remdesivir against COVID-19, and is the first domestically produced deuterium targeting the COVID-19 .

HY-145119S

Mindeudesivir
GS-621763-d₁ is the deuterium labeled GS-621763 (HY-145119) . GS-621763, an orally bioavailable proagent of GS-441524, shows antiviral activity against SARS-CoV-2 pathogenesis in mice .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

VV

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds